背景
肿瘤细胞表面表达的靶抗原是抗体药物偶联物（ADC）识别肿瘤细胞并引导细胞毒性有效载荷进入癌细胞的关键因素。因此，选择适当的靶抗原是设计ADC药物的首要考量。理想的靶抗原应具备以下特征:
特异性表达：靶抗原应在肿瘤细胞中高度特异性或主要表达，而在正常组织中表达水平较低或几乎不表达[1]，以减少脱靶效应及相关毒性。理想情况下，靶抗原应位于细胞表面或细胞外域，而非细胞内抗原，以便抗体药物偶联物能够在循环系统中有效识别并结合。
非分泌性：靶抗原应为非分泌型，避免抗原的过度分泌造成循环中抗原-抗体复合物的非特异性结合，这会导致ADC在肿瘤部位外的非特异性结合，从而降低药物的靶向性并可能增加安全性风险[2]。
内化特性：靶抗原与抗体结合后，应能有效内化进入肿瘤细胞，确保ADC复合物通过内吞作用进入细胞，继而通过适当的细胞内转运途径促进细胞毒性载荷的迅速释放[3]，以发挥抗肿瘤效应。
ACROBiosystems百普赛斯开发了90+高质量ADC药物靶点蛋白，覆盖Human、Mouse、Cynomolgus、Rat等多个种属及多种标签，具有高纯度及高生物活性，可用于免疫、抗体筛选、种属交叉验证、质控放行、药代动力学研究等多种应用场景。
产品优势
90+ ADC热门靶点蛋白全覆盖；
多种属，多标签；
蛋白均一结构及高纯度经SEC-MALS验证；
高生物活性经ELISA/SPR/BLI/FACS等验证。
验证数据
纯度经SEC-MALS验证
The purity of Mouse PSMA Protein, Fc Tag (Cat. No. PSA-M5266) is more than 90% and the molecular weight of this protein is around 240-280 kDa verified by SEC-MALS.
The purity of Biotinylated Human LRRC15, His,Avitag (Cat. No. LR5-H82E4) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
与抗体的结合活性经ELISA验证
Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human PSMA, His Tag (Cat. No. PSA-H52H3) with a linear range of 2-39 ng/mL (QC tested).
申请 Protocol
Immobilized Human TROP-2, His Tag (Cat. No. TR2-H5223) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
申请 Protocol
Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.2-3 ng/mL (QC tested).
申请 Protocol
Immobilized Human B7-H4, His Tag (Cat. No. B74-H5222) at 2 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).
申请 Protocol
与抗体的结合活性经SPR验证
Captured Trop2 antibody on CM5 chip via anti-mouse antibodies surface can bind Human TROP-2, His Tag (Cat. No. TR2-H5223) with an affinity constant of 5.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
申请 Protocol
Anti-Cadherin-17 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Cadherin-17, His Tag (Cat. No. CA7-H52H3) with an affinity constant of 2.9 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
申请 Protocol
Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Human Nectin-4, His Tag (Cat. No. NE4-H52H3) with an affinity constant of 58.2 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
申请 Protocol
Biotinylated Human FOLR1, His,Avitag (Cat. No. FO1-H82E2) immobilized on SA Chip can bind Folic acid-BSA with an affinity constant of 83.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
申请 Protocol
与抗体的结合活性经BLI验证
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
申请 Protocol
Loaded Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His,Avitag (Cat. No. RO1-H82E6) on SA Biosensor, can bind Zilovertamab with an affinity constant of 0.252 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
申请 Protocol
Star Ribbon预染蛋白Marker蛋白质标记物是生物研究和药物开发的重要组成部分。无论是用于蛋白质电泳还是western blot，我们的预染色蛋白质标记物帮助您快速确定目标蛋白质的分子量或评估转移效率。Fc受体蛋白治疗性抗体的功效取决于Fab片段及其对目标抗原的结合活性，还取决于Fc片段及其与关键Fc受体的相互作用。因此，在抗体工程中候选物必须针对一系列受体进行测试。探索我们的重组Fc受体蛋白质的全面收藏！
膜杰作
Star Staining
